ABSCIENCES (EPA:AB) AB Science announced that it has received new authorizations to resume patient enrollment in its Phase 3 studies of masitinib

Transparency directive : regulatory news

14/09/2021 18:01


Other stories

25/09/2021 20:08
25/09/2021 17:56
25/09/2021 16:36
25/09/2021 17:10
25/09/2021 19:08
25/09/2021 20:19
25/09/2021 15:35
25/09/2021 09:50
25/09/2021 16:35
25/09/2021 17:30
25/09/2021 10:15
25/09/2021 18:37
25/09/2021 16:02
25/09/2021 16:00
25/09/2021 19:41
25/09/2021 17:00
24/09/2021 17:48
25/09/2021 08:00
25/09/2021 18:22
24/09/2021 11:12
24/09/2021 21:30
25/09/2021 16:05
25/09/2021 13:00
25/09/2021 14:16
25/09/2021 18:46
25/09/2021 12:09
25/09/2021 18:57
25/09/2021 17:36
25/09/2021 17:26
25/09/2021 20:02
24/09/2021 04:01
24/09/2021 21:56
24/09/2021 11:22
24/09/2021 11:45
25/09/2021 11:19
24/09/2021 18:00
25/09/2021 10:43
25/09/2021 18:04